Google Doodle! Thanks Dr Salk!!!

Google Doodle celebrates Dr Salk, who developed one of the best and most effective vaccines ever.


Comments

Post a Comment

Popular posts from this blog

HepB and Autism

The paper by Gallagher and Goodman published in 2010 generated some online discussions. Since I could not get the original paper, I will repost some of the comments made by others. A post made in  https://leftbrainrightbrain.co.uk/2009/09/17/another-weak-study-proves-vaccines-cause-autism/  shows an analysis of the study and subsequent comments made. Thank you. What did they do? They looked at data from the National Health Interview Studies, and looked at autism and hepatitis B vaccination. They used surveys from 1997 to 2002, with children aged from 3 to 17. Mr. Kirby was kind enough to post an  image of the poster  to the EOHarm group. The autism group had 33 kids total. Of these, 9 of 31 (29%) were given the HepB vaccine. Compare this to 1,258 of 7,455 (17%) of the non-autism group who were given the HepB. 9 out of 31. Are the red flags up yet? They should be. Take for example kids aged 17 in the 1997 survey. When were they born? That’s right, 1...
Read more

Coronavirus and Vaccine Development

Coronavirus Vaccine Update: In addition to VBI Vaccines Inc. (Ottawa, Canada), the following firms are as of 27 March 2020 beginning Phase 1 testing Phase I vaccine candidates   Company:  Moderna Vaccine candidate:  mRNA-1273 Details:  Moderna is the Massachusetts-based biotech company behind mRNA-1273, a vaccine candidate developed using prior studies of related coronaviruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Study Design:  A Phase 1, open-label, dose-ranging clinical trial of 45 healthy participants between 18-55 years old Institution:   Kaiser Permanente Washington Health Research Institute Status:  Recruiting completed 19 March 2020 ClinicalTrials.gov Identifier:   NCT04283461 Funding:  NIAID   Company:  CanSino Biologics Vaccine candidate:  Ad5-nCoV Details:  China’s CanSino Biologics has developed a recombinant novel coronavirus vaccine that incorporates...
Read more

5 year hiatus from vaccines, but not from science

I am awe-struck by the mortality and speed of infection with which the SARS-coronavirus-2 (Covid-19) pandemic is currently sweeping the globe. After a stint in the health and wellness industry, promoting randomized controlled trials in the dietary supplement industry, I came back to vaccinology, exploring the clinical benefit of hepatitis B vaccines. In addition to working on clinical trials in hepatitis B, my previous experience as a scientific evaluator examining the adverse effects of drugs has given me the motivation to examine some cases of neurological disorders attributed to hepatitis B vaccines given to neonates and children. I will devote this and the subsequent posts to this topic.
Read more